MX2012010560A - Composicion para inhibir metastasis de cancer que contiene proteina de fusion dlk1-fc como ingrediente activo. - Google Patents
Composicion para inhibir metastasis de cancer que contiene proteina de fusion dlk1-fc como ingrediente activo.Info
- Publication number
- MX2012010560A MX2012010560A MX2012010560A MX2012010560A MX2012010560A MX 2012010560 A MX2012010560 A MX 2012010560A MX 2012010560 A MX2012010560 A MX 2012010560A MX 2012010560 A MX2012010560 A MX 2012010560A MX 2012010560 A MX2012010560 A MX 2012010560A
- Authority
- MX
- Mexico
- Prior art keywords
- fusion protein
- dlk1
- cancer metastasis
- active ingredient
- composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/809—Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención involucra la construcción de un vector de expresión recombinante que involucra la combinación de un gen dominio Fc del anticuerpo IgG de la región extracelular de DLK1, y la expresión y purificación de la proteína de fusión DLK1-Fc en células 293E, y se ha confirmado que la proteína de fusión DLK1-Fc reduce notablemente la migración de la célula cancerígena y que es eficaz como un fármaco para un concepto para la supresión práctica de la metástasis del cáncer a través del cálculo del parámetro farmacocinético. La presente invención puede utilizarse ventajosamente como un ingrediente activo en una composición para inhibir la metástasis del cáncer ya que la proteína de fusión DLK1-Fc es más estable que la proteína no de fusión, reduce notablemente la migración del cáncer en varias cepas de células cancerígenas y tiene un efecto inhibidor de la metástasis impresionante aún a una baja concentración.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020100023180A KR100982170B1 (ko) | 2010-03-16 | 2010-03-16 | DLK1―Fc 융합 단백질을 유효성분으로 함유하는 암 전이 억제용 조성물 |
PCT/KR2010/002277 WO2011115323A1 (ko) | 2010-03-16 | 2010-04-13 | 디엘케이원-에프씨 융합 단백질을 유효성분으로 함유하는 암 전이 억제용 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2012010560A true MX2012010560A (es) | 2012-12-10 |
MX342222B MX342222B (es) | 2016-09-21 |
Family
ID=43010111
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012010560A MX342222B (es) | 2010-03-16 | 2010-04-13 | Composicion para inhibir metastasis de cancer que contiene proteina de fusion dlk1-fc como ingrediente activo. |
Country Status (11)
Country | Link |
---|---|
US (1) | US8785392B2 (es) |
EP (1) | EP2548887B1 (es) |
JP (1) | JP5367905B2 (es) |
KR (1) | KR100982170B1 (es) |
CN (1) | CN102341408B (es) |
AU (1) | AU2010348423B2 (es) |
BR (1) | BR112012023416A2 (es) |
CA (1) | CA2792413C (es) |
MX (1) | MX342222B (es) |
RU (1) | RU2531756C2 (es) |
WO (1) | WO2011115323A1 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100982170B1 (ko) | 2010-03-16 | 2010-09-15 | 한국생명공학연구원 | DLK1―Fc 융합 단백질을 유효성분으로 함유하는 암 전이 억제용 조성물 |
WO2012138102A2 (ko) * | 2011-04-04 | 2012-10-11 | 한국생명공학연구원 | Dlk1 특이적 인간 항체 및 이를 포함하는 약학적 조성물 |
WO2012138100A2 (ko) * | 2011-04-04 | 2012-10-11 | 한국생명공학연구원 | Dlk1 세포 외 수용성 도메인을 포함하는 액티빈 수용체 타입 2b 억제제 |
KR101461706B1 (ko) | 2011-04-04 | 2014-11-18 | 한국생명공학연구원 | Dlk1 세포 외 수용성 도메인을 포함하는 액티빈 수용체 타입 2b 억제제 |
CN102778566B (zh) * | 2011-05-07 | 2016-01-13 | 上海市肿瘤研究所 | Dlk1在肝癌诊断及预后判断中的应用 |
KR101995751B1 (ko) * | 2012-01-05 | 2019-07-03 | 주식회사 와이바이오로직스 | Dlk1 세포 외 수용성 도메인을 유효성분으로 포함하는 미오스타틴 저해제 |
WO2014129590A1 (ja) * | 2013-02-21 | 2014-08-28 | 国立大学法人九州大学 | Cyclin D1遺伝子発現抑制剤および抗腫瘍剤 |
CN105765063B (zh) | 2013-09-30 | 2021-05-07 | 中外制药株式会社 | 应用改变的辅助噬菌体制备抗原结合分子的方法 |
CN104711341B (zh) * | 2013-12-17 | 2019-10-22 | 上海市肿瘤研究所 | Dlk1基因在制备胃肠道间质瘤诊断试剂中的应用 |
WO2019050362A2 (ko) * | 2017-09-08 | 2019-03-14 | 주식회사 와이바이오로직스 | 인간 dlk1에 대한 항체 및 이의 용도 |
CN108130311B (zh) * | 2017-12-19 | 2020-12-08 | 柴怡 | 一种人原代结肠癌肝转移细胞株hcs1220 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
ES2151542T3 (es) * | 1992-12-11 | 2001-01-01 | Us Health | Gen del tipo delta expresado en tumores neuroendocrinos. |
EP0938332A4 (en) * | 1996-03-01 | 2003-05-28 | Imclone Systems Inc | USE OF DELTA-LIKE PROTEINS TO INHIBIT THE DIFFERENTIATION OF STEM CELLS |
US20020064855A1 (en) * | 1999-08-20 | 2002-05-30 | Ihor Lemischka | Genes that regulate hematopoietic blood forming stem cells and uses thereof |
JP2007531707A (ja) * | 2003-10-15 | 2007-11-08 | ピーディーエル バイオファーマ, インコーポレイテッド | IGの重鎖定常領域の位置250、314および/または428の変異誘発によるFc融合タンパク質血清半減期の改変 |
US8227578B2 (en) | 2006-11-10 | 2012-07-24 | Abe, Ikubo & Katayama | Anti-human dlk-1 antibody showing anti-tumor activity in vivo |
ES2527521T3 (es) * | 2008-03-17 | 2015-01-26 | Livtech Inc. | Anticuerpos antihumanos frente a Dlk-1 que tienen actividad antitumoral |
KR100982170B1 (ko) | 2010-03-16 | 2010-09-15 | 한국생명공학연구원 | DLK1―Fc 융합 단백질을 유효성분으로 함유하는 암 전이 억제용 조성물 |
-
2010
- 2010-03-16 KR KR1020100023180A patent/KR100982170B1/ko active IP Right Grant
- 2010-04-13 US US13/142,818 patent/US8785392B2/en active Active
- 2010-04-13 EP EP10838389.4A patent/EP2548887B1/en not_active Not-in-force
- 2010-04-13 RU RU2012143943/10A patent/RU2531756C2/ru not_active IP Right Cessation
- 2010-04-13 CN CN201080013202.XA patent/CN102341408B/zh not_active Expired - Fee Related
- 2010-04-13 MX MX2012010560A patent/MX342222B/es active IP Right Grant
- 2010-04-13 BR BR112012023416A patent/BR112012023416A2/pt not_active Application Discontinuation
- 2010-04-13 CA CA2792413A patent/CA2792413C/en not_active Expired - Fee Related
- 2010-04-13 JP JP2012505813A patent/JP5367905B2/ja not_active Expired - Fee Related
- 2010-04-13 AU AU2010348423A patent/AU2010348423B2/en not_active Ceased
- 2010-04-13 WO PCT/KR2010/002277 patent/WO2011115323A1/ko active Application Filing
Also Published As
Publication number | Publication date |
---|---|
EP2548887B1 (en) | 2015-05-27 |
US8785392B2 (en) | 2014-07-22 |
WO2011115323A1 (ko) | 2011-09-22 |
CN102341408B (zh) | 2014-09-10 |
JP5367905B2 (ja) | 2013-12-11 |
EP2548887A1 (en) | 2013-01-23 |
US20130202592A1 (en) | 2013-08-08 |
BR112012023416A2 (pt) | 2017-03-21 |
CA2792413A1 (en) | 2011-09-22 |
CN102341408A (zh) | 2012-02-01 |
KR100982170B1 (ko) | 2010-09-15 |
AU2010348423A1 (en) | 2012-10-25 |
RU2531756C2 (ru) | 2014-10-27 |
AU2010348423B2 (en) | 2014-04-10 |
JP2012513775A (ja) | 2012-06-21 |
CA2792413C (en) | 2015-12-01 |
MX342222B (es) | 2016-09-21 |
EP2548887A4 (en) | 2013-12-04 |
RU2012143943A (ru) | 2014-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2012010560A (es) | Composicion para inhibir metastasis de cancer que contiene proteina de fusion dlk1-fc como ingrediente activo. | |
MX366155B (es) | Celulas para producir iduronato-2-sulfatasa recombinante. | |
AU2013211824A8 (en) | Fusion proteins comprising IgG2 hinge domains | |
CL2014002166A1 (es) | Proteína de fusión de factor viii recombinante que comprende al polipéptido recombinante extendido xten; composición farmacéutica que la comprende; ácido nucleico que la codifica; vector; célula huésped; método de producción; y uso para tratar una coagulopatía, tal como hemofilia. | |
BR112015022119A2 (pt) | Polipeptídeo, composto conjugado, composição farmacêutica, ácido nucleico, vetor, células hospedeiras procariótica e eucariótica, método de produção de um polipeptídeo, e, método de tratamento | |
TN2014000488A1 (en) | Antibody formulation | |
PH12015502441B1 (en) | Anti-il-4/anti-il-13 bispecific antibody formulations | |
TR201910103T4 (tr) | Anti-fcrn antikorları. | |
CA2811364C (en) | Methods and compositions for inhibiting viral entry into cells | |
GB2513768A (en) | Complexes of cytomegalovirus proteins | |
PE20191815A1 (es) | Formulaciones acuosas estables de adalimumab | |
MX2011013455A (es) | Diseño de moleculas de fc de anticuerpo estables y libres de agregacion a traves del diseño de la interfase del dominio de ch3. | |
JP2013231081A5 (es) | ||
MX2016005762A (es) | Region variable de anticuerpo modificada que contiene molecula de union al antigeno. | |
MX2018015914A (es) | Anticuerpos frente a los ligandos del receptor b1 de bradicinina. | |
GB201106498D0 (en) | Electrochemical pH sensor | |
SG10201909517WA (en) | Learning and memory improver | |
EA201590061A1 (ru) | Фармацевтическая композиция | |
GB201013215D0 (en) | Expression of antibody or a fragment thereof in lactobacillus | |
IN2015DN00344A (es) | ||
WO2012020108A3 (en) | Multimeric inhibitors of viral fusion and uses thereof | |
WO2011115458A3 (ko) | 자가 면역 질환 예방 및 치료용 TNF-α와 IL-21 이중 길항제 | |
WO2012141794A3 (en) | Crystal structure and peptide inhibitors of hausp deubiquitinase | |
MX353734B (es) | Metodo para producir proteinas autologas. | |
MX2022007399A (es) | Variantes de alfa-glucosidasa ácida diseñadas. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |